Novo Nordisk reports Wegovy helped children lose weight in late-stage trial
Novo Nordisk announced results from a late-stage trial showing semaglutide, the active ingredient in Wegovy, reduced obesity in children aged 6 to under 12. Reuters reported that 40.4% of treated children were no longer classified as obese. The results support potential expansion of Wegovy's use to pediatric populations.
3
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Wall Street Journal
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
First to report
- Reutersfirst
- Wall Street Journal+7.2 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Both outlets report the same trial results; Reuters leads with the 40.4% no longer obese statistic while WSJ frames it more broadly as helped children lose weight.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Novo Nordisk says semaglutide cut obesity rates in young children in trial”
“Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial”
3 tracked claims across 2 outlets
Fact ledger
All3Claimed1Corroborated2
1/2
Claimed
40.4% of treated children were no longer classified as obese
Corroborated
Disputed
2 more tracked claimsSign up free to see the full ledger